<DOC>
	<DOCNO>NCT00770562</DOCNO>
	<brief_summary>This study compare efficacy , safety , pharmacokinetics standard treatment versus standard treatment plus MabThera patient ITP . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Evaluating Addition MabThera ( Rituximab ) Standard Treatment Patients With Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Chlorpheniramine</mesh_term>
	<criteria>adult patient &gt; =18 year age ; untreated ITP . ITP relapse ; positive test result HIV hepatitis B C ; active infection require systemic therapy ; malignancy within 3 year study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>